Mechanism of Action of Ponatinib
Introduction Ponatinib is an oral targeted anticancer drug used in selected Philadelphia chromosome-positive leukemias. It is marketed under the brand name Iclusig. Pharmacologically, ponatinib belongs to the BCR-ABL tyrosine kinase inhibitor class and is often described as a third-generation BCR-ABL inhibitor. Philadelphia chromosome-positive chronic myeloid leukemia, or Ph+ CML, and Philadelphia chromosome-positive acute lymphoblastic leukemia, … Read more